Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of ELICERA THERAPEUTICS AB
No Price
Closing Price XSTO 30.04.2026:
3,34 SEK
30.04.2026 10:52
Current Prices from ELICERA THERAPEUTICS AB
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ STOCKHOLM AB
ELIC.ST
SEK
30.04.2026 10:52
3,34 SEK
0,18 SEK
+5,70 %
Share Float & Liquidity
Free Float42,50 %
Shares Float20,63 M
Shares Outstanding48,54 M
Company Profile for ELICERA THERAPEUTICS AB Share
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.
